Sorrento Therapeutics (NASDAQ:SRNE) received a $30.00 price objective from HC Wainwright in a research note issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 305.41% from the company’s current price.
Several other research analysts have also recently issued reports on SRNE. Oppenheimer set a $6.00 target price on Sorrento Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 15th. BidaskClub raised Sorrento Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, ValuEngine raised Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $13.67.
Shares of Sorrento Therapeutics (NASDAQ SRNE) traded down $0.35 during trading hours on Tuesday, reaching $7.40. The company’s stock had a trading volume of 3,890,878 shares, compared to its average volume of 3,039,800. The stock has a market capitalization of $584.47, a PE ratio of -17.62 and a beta of 1.04. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.54 and a quick ratio of 0.54. Sorrento Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $8.05.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.